Intravitreal Polymer Implants for Linear Ocular Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current intravitreal implants for treating ocular diseases release therapeutic agents for short durations, requiring frequent injections and are associated with adverse effects such as cataract formation and increased intraocular pressure, necessitating a safer and more effective delivery system for prolonged therapeutic agent release.
Innovation Solution
A biodegradable polymer matrix comprising a mixture of biodegradable polyester amide, poly(D,L-lactide), and poly(D,L-lactide-co-glycolide) polymers, homogenously dispersed with therapeutic agents, formulated for intravitreal administration to release agents in a substantially linear manner for extended periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If intravitreal implants are used to deliver therapeutic agents, then the duration of treatment is extended, but the frequency of injections increases and adverse effects occur
Solution Approach 1:
The patent modifies the polymer composition parameters by incorporating specific ratios of PLGA to PLA polymers with controlled molecular weights and lactide:glycolide ratios. This parameter optimization enables extended therapeutic agent release (6-12 months) while maintaining biocompatibility and minimizing adverse effects through controlled degradation rates
Solution Approach 2:
The invention uses composite biodegradable polymer materials combining PLGA and PLA in specific ratios (e.g., 70:30, 80:20) to achieve synergistic effects. The composite structure provides both extended release capability and reduced toxicity compared to single-polymer systems, addressing the contradiction between duration and safety
2Reliability
If repeated bolus injections of corticosteroids are administered, then therapeutic effect is achieved, but adverse effects such as cataract formation and increased intraocular pressure occur
Solution Approach 1:
The patent incorporates the therapeutic agent into the biodegradable polymer matrix during manufacturing, creating a pre-formulated implant that releases the agent continuously over time. This preliminary action eliminates the need for repeated injections, providing sustained therapeutic effect while avoiding the cumulative adverse effects of multiple corticosteroid administrations
Solution Approach 2:
The implant design ensures continuous release of the therapeutic agent through controlled polymer degradation. The biodegradable matrix maintains a sustained concentration of the agent in the vitreous humor over 6-12 months, providing uninterrupted therapeutic action without the peaks and valleys associated with repeated bolus injections
3Loss of time
If intravitreal implants are used for extended release, then injection frequency is reduced, but the complexity of the delivery system increases
Solution Approach 1:
The patent optimizes polymer parameters (molecular weight, lactide:glycolide ratio, PLGA:PLA ratio) to achieve extended release without requiring complex device structures. By controlling the chemical composition and degradation kinetics of the polymer matrix, the system extends treatment duration through material properties rather than mechanical complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new pharmaceutical composition enables sustained release of therapeutic agents for up to six months, reducing the frequency of injections and minimizing adverse effects, improving patient compliance and safety.
Implementation Method 1
various biodegradable polymers have been used to produce such intravitreal implants. Particular examples of such polymers are poly(lactic-co-glycolic acid) (PLGA), and poly(lactic acid) or polylactic acid or polylactide (PLA)
Implementation Method 2
At least one therapeutic agent or an analog or derivative thereof, a pharmaceutically acceptable salt, zwitterion, polymorph or solvate thereof is homogenously dispersed within the polymer matrix
Data Source
AI summary
Provided herein are pharmaceutical compositions, intravitreal implants and particle suspensions comprising a polymer matrix and at least one therapeutic agent that is released in a substantially linear manner for a particular duration.